A Delight note on European Journal of Clinical Oncology

Ravi Kaushik*
Department of Physiology, Delhi University, Delhi, India

Corresponding Author*
Ravi Kaushik
Department of Physiology, Delhi University, Delhi, India
E-mail: ravikas@gmail.com

Copyright: 2020 Kaushik R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received 05 Nov 2020; Accepted 25 Nov 2020; Published 2 Dec 2020

Editorial

I am delighted to announce that the European Journal of Clinical Oncology (EJCO) is a new journal that has given me the opportunity to present the journal's accomplishments in 2019. As we know, the newly coined journal EJCO is under production for indexing by various indexing agencies. At the given time, EJCO published all the issues and preprints were also published and dispatched online within 30 days of the publication of the report. EJCO accepts all manuscripts, such as academic articles, case studies, review papers, brief commentaries, mini reviews, etc EJCO released two study papers, one case report, one mini review and one commentary in volume 1 issue 1 and also published volume 1 issue 2 of 2019, announcing the conference and awards that will take place in 2020. Cancer is a big growth problem, and it weakens Socio-economic advances worldwide. It's calculated that the number of cancer patients will rise from 12 to 12. Million by 2030 in the year 2008 to 22 million. The European Journal of Clinical Oncology is strategically placed in the At this moment, the setting for clinical trials to help tackle the danger of By helping to develop novel treatment methods, cancer And providing new insights into the processes that underlie this A complex disorder. This journal does not charge its reader and the journal any kind of fees. Offer readers complete access to the post. The reach of the diary Cancer Genetics, Breast Cancer, Colorectal Cancer, Immune Treatment for Cancer, Chemotherapy, Cancer From anatomy. All 5 papers submitted to this journal went through a peer review. Any of them are subject to revision and evaluation procedures. Remaining records are accepted for further review and processing. The time needed for the publication of an article is quite long. Within 7 days of acceptance by fewer, the article is published by from the editors. This journal's additional quality is that the Editors are sole decision-makers on the publication of documents. Method for review and peer review completed within the specified given time. If any manuscript is not approved by peer review, the author's approach gave the author another opportunity to develop the Manuscript. Internet broadcasting and various social media are used by the journal. Media outlets such as Twitter, LinkedIn, Facebook Updates on what's going on in the newspaper to make people aware of About trending oncology-related subjects.

I'd like to get a Recognize the input of all editors, reviewers, and the During the final editing of the published document, other supporting populations articles and the assistance given by the editorial assistant Getting the EJCO problem out on time.

I would like to take this time to acknowledge the input of all members of the Press and their support during the final edition of the published papers this makes it a nice publishing house. I am very grateful to the journals once again. That gave me the chance to explain this prominent journal.

Cite this article: Ravi Kaushik, A Delight Note on European Journal of Clinical Oncology. Eur J Clin Oncol, 2020, 2(3), 001.